Börse:
32,500€
-0,31%
Echtzeit-Aktienkurs PTC Therapeutics
Bid:
32,000€
Ask:
33,000€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 1,64 Mrd. EUR (50,61 Mio. x 32,500€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 29,98 | 13,43 | 6,96 | 6,21 |
| KGV | - | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der PTC Therapeutics Aktie
Börsenkurse PTC Therapeutics
| Börse Stuttgart | 32,000€ | 0 | 33,000€ | 0 | 32,500€ | -0,31% |
| Euro Indikation | 32,000€ | 0 | 33,000€ | 0 | 32,500€ | -0,31% |
| Tradegate | 32,200€ | 187 | 32,800€ | 181 | 32,500€ | -1,52% |
| Lang & Schwarz | 32,400€ | 364 | 32,600€ | 364 | 32,500€ | -1,52% |
| Dollar Indikation | 35,804$ | 0 | 36,777$ | 0 | 36,291$ | -1,36% |
Fundamentaldaten der PTC Therapeutics Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 264,73 Mio. | -128,11 Mio. | -128,08 Mio. | -2,75 | 0,00% | - | 6,21 |
| 2017 | 194,39 Mio. | -77,67 Mio. | -79,00 Mio. | -2,02 | 0,00% | - | 6,96 |
| 2016 | 82,71 Mio. | -141,54 Mio. | -142,11 Mio. | -4,17 | 0,00% | - | 13,43 |
| 2015 | 36,77 Mio. | -169,96 Mio. | -170,45 Mio. | -5,07 | 0,00% | - | 29,98 |
| 2014 | 25,25 Mio. | -98,45 Mio. | -93,75 Mio. | -2,97 | 0,00% | - | 42,35 |
| 2013 | 34,70 Mio. | -51,57 Mio. | -48,18 Mio. | -5,18 | 0,00% | - | 22,30 |
| 2012 | 33,95 Mio. | -26,24 Mio. | 133,34 Mio. | 4,73 | 0,00% | 6,88 | 27,01 |
| 2011 | 105,41 Mio. | 28,60 Mio. | 30,91 Mio. | 1,10 | 0,00% | 29,65 | 8,70 |
Profil der PTC Therapeutics Aktie
PTC Therapeutics, Inc. engages in the discovery, development, and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology. Its preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease. It product, candidate ataluren, is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. The company was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen